BUPRENORPHINE SANDOZ (Sandoz Pty Ltd)
Product name
BUPRENORPHINE SANDOZ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
171 working days (255)
Active ingredients
buprenorphine
Registration type
New generic medicine
Indication
BUPRENORPHINE SANDOZ (dermal patch) is indicated for management of moderate to severe pain.